-
公开(公告)号：WO2004094463A2
公开(公告)日：2004-11-04
申请号：PCT/US2004/012195
申请日：2004-04-19
Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. , JOHNSON, Howard, M. , SUBRAMANIAM, Prem, S.
Inventor： JOHNSON, Howard, M. , SUBRAMANIAM, Prem, S.
IPC: C07K7/00
CPC classification number: C07K14/4703 , A61K38/00 , C07K14/71
Abstract: The subject invention concerns peptide molecules that specifically inhibit the enzymatic function of tyrosine kinases, including the JAK and EGF receptor (EGFR) family of kinases, to autophosphorylate, i.e., to transfer a phosphate group from ATP to an amino acid in the kinase. Phosphorylation of proteins is the most fundamental method for signal transduction among proteins in a cell. Inhibition of tyrosine kinase autophosphorylation activities inhibits the enzyme's signaling and shuts down the functioning pathways originating from the enzyme. The JAK2 and EGFR tyrosine kinases are involved in both inflammatory disorders and cancer. In these disorders, the tyrosine kinases can often be activated in an uncontrolled fashion. The subject application also concerns antibodies that bind to a tyrosine kinase autophosphorylation site. The subject invention also concerns pharmaceutically acceptable formulations of the subject peptides and antibodies, and methods for treating inflammatory and oncological disorders by inhibiting tyrosine kinase signaling in these situations by administering a peptide or antibody of the present invention.
Abstract translation: 本发明涉及特异性抑制酪氨酸激酶（包括JAK和EGF受体（EGFR）激酶）家族酶促功能的肽分子，其自磷酸化，即将磷酸基团从ATP转移到激酶中的氨基酸。 蛋白质的磷酸化是细胞中蛋白质之间信号转导的最基本的方法。 抑制酪氨酸激酶自身磷酸化活性抑制酶的信号传导并且关闭源自酶的功能途径。 JAK2和EGFR酪氨酸激酶参与炎性疾病和癌症。 在这些疾病中，酪氨酸激酶通常可以以不受控制的方式活化。 本申请还涉及结合酪氨酸激酶自身磷酸化位点的抗体。 本发明还涉及本发明肽和抗体的药学上可接受的制剂，以及通过施用本发明的肽或抗体在这些情况下通过抑制酪氨酸激酶信号传导来治疗炎症和肿瘤疾病的方法。
-
公开(公告)号：WO1997039127A1
公开(公告)日：1997-10-23
申请号：PCT/US1997006114
申请日：1997-04-11
Applicant: UNIVERSITY OF FLORIDA
IPC: C12N15/21
CPC classification number: C07K14/555 , A61K38/00 , C07K14/56 , C07K16/249 , C07K2319/00 , C07K2319/02
Abstract: The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second segment that contains the C-terminal amino acid sequence of a non-tau interferon type I polypeptide. The two segments are joined in the region of a mature interferon polypeptide between about residues 8 and 37. Also described are nucleic acid sequences encoding such interferon fusion polypeptides, expression vectors containing such sequences, and therapeutic applications of the interferon fusion polypeptides. The therapeutic applications include antiviral and anticellular proliferation applications. One advantage of the interferon fusion polypeptides of the present invention is that they do not have cytotoxic side-effects when used to treat cells.
Abstract translation: 本发明描述了由包含干扰素-τ多肽的N-末端氨基酸序列的第一片段形成的混合干扰素融合多肽，以及包含非τ型干扰素I型的C末端氨基酸序列的第二片段 多肽。 两个片段在大约残基8和37之间的成熟干扰素多肽的区域中连接。还描述了编码这种干扰素融合多肽的核酸序列，含有这种序列的表达载体和干扰素融合多肽的治疗应用。 治疗应用包括抗病毒和抗细胞增殖应用。 本发明的干扰素融合多肽的一个优点是当它们用于治疗细胞时它们不具有细胞毒性副作用。
-
公开(公告)号：EP0914435B1
公开(公告)日：2005-08-03
申请号：EP97918591.5
申请日：1997-04-11
Applicant: UNIVERSITY OF FLORIDA
Inventor： JOHNSON, Howard, M. , SUBRAMANIAM, Prem, S. , PONTZER, Carol, H.
CPC classification number: C07K14/555 , A61K38/00 , C07K14/56 , C07K16/249 , C07K2319/00 , C07K2319/02
Abstract: The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second segment that contains the C-terminal amino acid sequence of a non-tau interferon type I polypeptide. The two segments are joined in the region of a mature interferon polypeptide between about residues 8 and 37. Also described are nucleic acid sequences encoding such interferon fusion polypeptides, expression vectors containing such sequences, and therapeutic applications of the interferon fusion polypeptides. The therapeutic applications include antiviral and anticellular proliferation applications. One advantage of the interferon fusion polypeptides of the present invention is that they do not have cytotoxic side-effects when used to treat cells.
-
公开(公告)号：EP0914435A1
公开(公告)日：1999-05-12
申请号：EP97918591.0
申请日：1997-04-11
Applicant: UNIVERSITY OF FLORIDA
Inventor： JOHNSON, Howard, M. , SUBRAMANIAM, Prem, S. , PONTZER, Carol, H.
CPC classification number: C07K14/555 , A61K38/00 , C07K14/56 , C07K16/249 , C07K2319/00 , C07K2319/02
Abstract: The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second segment that contains the C-terminal amino acid sequence of a non-tau interferon type I polypeptide. The two segments are joined in the region of a mature interferon polypeptide between about residues 8 and 37. Also described are nucleic acid sequences encoding such interferon fusion polypeptides, expression vectors containing such sequences, and therapeutic applications of the interferon fusion polypeptides. The therapeutic applications include antiviral and anticellular proliferation applications. One advantage of the interferon fusion polypeptides of the present invention is that they do not have cytotoxic side-effects when used to treat cells.
-
-
-
Search Results
4
records
(took 0.03 seconds)
